Choroidal melanoma is the most common primary intraocular ... to identify the high-risk patients who will require treatment with targeted adjuvant agents before metastasis occurs.

The summer of 2023 saw the approval of a new treatment option for certain ... in early-stage choroidal melanoma. Bel-sar is from a novel class of virus-like drug conjugate therapies that Boston ...

While melanoma is much less common than other types of skin cancer, it is the most serious because it is more likely to ...

The lab of The Wistar Institute's Jessie Villanueva, Ph.D., has identified a new strategy for attacking treatment-resistant ...

As part of The Wistar Institute's Melanoma Research Center, the Villanueva lab pursues new ways to overcome the challenge of melanoma drug resistance. In this paper, the group took aim at melanomas ...

Modern Retina - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic community.

Upon Opdualag’s approval in 2022 as a first-in-class cancer immunotherapy, Bristol Myers Squibb was anxious to explore its potential in a variety of indications. | Bristol Myers Squibb is striking out ...

The lab of The Wistar Institute's Jessie Villanueva, Ph.D., has identified a new strategy for attacking treatment-resistant melanoma: inhibiting the gene S6K2. .

The treatment landscape for melanoma saw significant advancements in 2024, as highlighted by Elisa Funck-Brentano, MD, PhD, from Ambroise-Paré Hospital in Paris, France, during her presentation ...

During a Case-Based Roundtable® event, Thach-Giao Truong, MD, discussed goals and barriers to treatment when using ...